Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations The expanding GLP-1 family of drugs and their expanded potential use cases Back last December I wrote about the The New Obesity Breakthrough Drugs, and specifically the striking results in randomized trials for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss, their putative mechanism(s), while also emphasizing their very high cost, lack of plan for successful weaning, and exacerbation of health inequities
At 72 weeks, tirzepatide vs semaglutide produced 20.2% mean weight loss versus 13.7% in SURMOUNT-5, the first randomized head-to-head trial between them (NEJM, May 2025)
It mimics the GLP-1 hormone that targets areas of the brain that regulate appetite and food intake, making it a critical tool for medical weight loss supervised by specialists like OBGYNs
The average SNR values in each VOI were substantially higher than those reported in the majority of MRS studies [23, 57]
AltRx involves prescription weight loss injections, which means both effects and risks need to be taken seriously
Vitamin B12 is needed for physical growth and development also needed for forming red blood cells in the bones
US$ 25.40
US$ 29.62
US$ 29.44
US$ 28.44
US$ 29.41
US$ 21.96
